AL
Aldeyra The
ALDX · NASDAQ
$1.36 -1.45% (-$0.02)
1M -10.53%
Market Cap $83.2M
P/E Ratio -
Div. Yield -
ROE 53.14%
Bulios Fair Price
$1.15
15.4% downside
Current Price
$1.36
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ALDX is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
83 /100
Cheap P/B 2.20x
PEG N/A
P/S N/A
Growth
0 /100
Declining Book val. growth 33.58%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROE 53.14%
ROA 48.49%
Asset turnover 0.00x
Debt
69 /100
Low Current ratio 4.91x
Int. coverage -15.24x
Debt/Equity 0.00x
Stability
40 /100
Moderate EPS volatility 50.17%
Profitable years 0
Beta 1.19x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ALDX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Todd C. Brady
Employees
6
Headquarters
Lexington
Upcoming events
04 NOV
Earnings
Upcoming earnings report